These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 22760691

  • 21. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [Abstract] [Full Text] [Related]

  • 22. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
    Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.
    Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
    [Abstract] [Full Text] [Related]

  • 23. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.
    Bone Marrow Transplant; 2018 Mar; 53(3):246-254. PubMed ID: 29255168
    [Abstract] [Full Text] [Related]

  • 24. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
    Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkun J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejczak W.
    Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
    [Abstract] [Full Text] [Related]

  • 25. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M.
    Haematologica; 2024 May 01; 109(5):1525-1534. PubMed ID: 37981892
    [Abstract] [Full Text] [Related]

  • 26. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E.
    Transfusion; 2012 Aug 01; 52(8):1785-91. PubMed ID: 22304442
    [Abstract] [Full Text] [Related]

  • 27. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N, Harvey RD, Nooka A, Flowers C, Kaufman J, Lonial S, Lechowicz MJ, Langston A, Lipscomb C, Gaylor C, Waller EK.
    Transfusion; 2015 Oct 01; 55(10):2351-7. PubMed ID: 26331348
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
    Gutiérrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mejía-Jaramillo G, Salazar-Riojas R, León AG, Colunga-Pedraza PR, Sotomayor-Duque G, Jaime-Pérez JC, Cantú-Rodríguez OG, Del Carmen Tarín-Arzaga L, Flores-Jiménez JA, Gómez-Almaguer D.
    Transfusion; 2019 Dec 01; 59(12):3721-3726. PubMed ID: 31618456
    [Abstract] [Full Text] [Related]

  • 31. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
    Keating GM.
    Drugs; 2011 Aug 20; 71(12):1623-47. PubMed ID: 21861545
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T.
    Eur J Haematol; 2011 Apr 20; 86(4):299-304. PubMed ID: 21198864
    [Abstract] [Full Text] [Related]

  • 36. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.
    J Clin Apher; 2013 Oct 20; 28(5):359-67. PubMed ID: 23765597
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F, Cavenaghi L, de Melo CM.
    Transfus Apher Sci; 2009 Apr 20; 40(2):91-5. PubMed ID: 19233728
    [Abstract] [Full Text] [Related]

  • 39. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.
    Biol Blood Marrow Transplant; 2012 Feb 20; 18(2):314-7. PubMed ID: 22001752
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.